These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 16416832)

  • 1. [Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy].
    Asano M; Taniwaki H; Tsuji D; Sato Y; Shimizu T
    Nihon Rinsho; 2005 Dec; 63 Suppl 12():450-3. PubMed ID: 16416832
    [No Abstract]   [Full Text] [Related]  

  • 2. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
    Shirai N; Furuta T
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():439-44. PubMed ID: 11979823
    [No Abstract]   [Full Text] [Related]  

  • 3. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
    Shirai N; Furuta T; Sugimoto M; Nakamura A
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():438-41. PubMed ID: 16363575
    [No Abstract]   [Full Text] [Related]  

  • 4. [Investigation about 3rd line eradication of H. pylori].
    Nakagawa S; Kato M; Shimizu Y; Nakagawa M; Asaka M
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():466-9. PubMed ID: 16363580
    [No Abstract]   [Full Text] [Related]  

  • 5. [Influence of cytochrome P450 2C19 genetic polymorphism on H. pylori eradication therapy].
    Hikichi T; Irisawa A; Abe C; Obara K; Sato Y
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():569-72. PubMed ID: 16363603
    [No Abstract]   [Full Text] [Related]  

  • 6. [Recent topics on important drugs for H. pylori eradication: Rabeprazole].
    Sugimoto M; Furuta T; Nakmura A; Shirai N
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():350-3. PubMed ID: 16363558
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment].
    Ohkusa T; Watanabe M
    Nihon Rinsho; 2001 Feb; 59(2):323-7. PubMed ID: 11218406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of non-response in Helicobacter pylori eradication trials.
    Klotz U; Treiber G; Schwab M
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1471. PubMed ID: 16105147
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
    J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent topics on important drugs for H. pylori eradication: Omeprazole].
    Kataoka H; Jho T; Itoh M
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():333-7. PubMed ID: 16363556
    [No Abstract]   [Full Text] [Related]  

  • 13. Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.
    Isomoto H; Inoue K; Furusu H; Nishiyama H; Shikuwa S; Omagari K; Mizuta Y; Murase K; Murata I; Kohno S
    Helicobacter; 2003 Apr; 8(2):111-9. PubMed ID: 12662378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
    Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M
    Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori.
    Schwab M; Schaeffeler E; Klotz U; Treiber G
    Clin Pharmacol Ther; 2004 Sep; 76(3):201-9. PubMed ID: 15371981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
    Furuta T; Takashima M; Shirai N; Xiao F; Hanai H; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Usefulness of new triple therapy containing PPI].
    Tanabe H; Watari J; Shibata N; Satoh T; Yokota K; Kohgo Y
    Nihon Rinsho; 2001 Feb; 59(2):314-8. PubMed ID: 11218404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
    Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.
    Furuta T; Sugimoto M; Shirai N; Matsushita F; Nakajima H; Kumagai J; Senoo K; Kodaira C; Nishino M; Yamade M; Ikuma M; Watanabe H; Umemura K; Ishizaki T; Hishida A
    Aliment Pharmacol Ther; 2007 Sep; 26(5):693-703. PubMed ID: 17697203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
    Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH
    Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.